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The retinoblastoma protein (pRb) and the pRb-related
proteins, p130 and p107, form the ‘pocket protein’
family of cell cycle regulatory factors. A well characteri-
zed function of these proteins is the cell cycle-dependent
regulation of E2F-responsive genes. The biological
activity of pocket proteins is regulated by phosphorylation
and for the founding member pRb it has been shown that
acetylation also has an important role in modulating its
function during the cell cycle. Here, we show that
hyperphosphorylated retinoblastoma 2 (Rb2)/p130 also
exists in an acetylated form in NIH3T3 cells. Acetylated
p130 is present in the nucleus but not in the cytoplasm.
Acetylation is cell cycle dependent, starting in S-phase
and persisting until late G2-period. Using recombinant
p130 and truncated forms for in vitro acetylation by the
acetyltransferase p300, we could identify K1079 in the
C-terminal part as the major acetylation site by mass
spectrometry. Minor acetylation sites were pinpointed to
K1068 and K1111 in the C-terminus, and K128 and K130
in the N-terminus. The human papilloma virus 16 protein-
E7 preferentially binds to acetylated p130 and signiﬁ-
cantly increases in vitro p130 acetylation by p300.
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The retinoblastoma gene family consists of three
members, retinoblastoma (Rb)/p105, p107 and Rb2/
p130. The family is also referred to as the ‘pocket
protein’ family, as these proteins are characterized by a
conserved pocket region through which they can bind
viral and cellular proteins, such as the E2F family of
transcription factors (Claudio et al., 2002; Du and
Pogoriler, 2006). The Rb family proteins have important
roles in proliferation control by transcriptional regula-
tion of cell cycle progression through E2F, especially at
the G1–S transition (Cobrinik, 2005); moreover, pocket
proteins can target chromatin modiﬁers to E2F promo-
ters and interact with chromatin remodeling enzymes
(Giacinti and Giordano, 2006; Macaluso et al., 2006).
Chromatin modifying enzymes not only modify
histones, but indeed a huge variety of non-histone
regulatory and structural proteins that interact with
chromatin, such as protooncogene and tumor suppres-
sor proteins, transcription factors and enzymes (Gu and
Roeder, 1997; Vervoorts et al., 2003; Zhang et al., 2003;
Choi et al., 2003; Meraner et al., 2006). Retinoblastoma
protein (pRb) has been shown to be acetylated by p300/
CBP, as well as P/CAF (Nguyen et al., 2004) and the
modiﬁcation changes its properties with respect to phos-
phorylation by cyclin-dependent kinases (Chan et al., 2001).
The cell cycle-dependent phosphorylation of more
than 20 distinct residues has been identiﬁed for Rb2/
p130 (Canhoto et al., 2000; Hansen et al., 1999, 2001).
The majority of sites can be phosphorylated by CDK-2,
4 or 6, predisposing p130 for ubiquitination, and thus
proteosomal degradation (Tedesco et al., 2002). How-
ever, in contrast to the common picture of pocket
protein inactivation through phosphorylation by
CDKs, p130 actively associates with E2F-4 in a distinct
phosphorylation state as cells enter G0 (Mayol et al.,
1996); this modiﬁcation state is independent from CDK
activity and has been ascribed to glycogen synthase
kinase 3 (Litovchick et al., 2004). Moreover, mapping of
phosphorylation sites revealed only 3 out of 22 CDK
consensus sites being conserved between pRB and p130,
whereas 10 phosphorylated serine/threonine residues
are conserved between p107 and p130, indicating
pronounced differences in the functional consequences
of modiﬁcation among the three pocket proteins.
We set out to study the posttranslational acetylation
of p130 during the cell cycle of NIH3T3 cells, as a
screening for acetylated non-histone nuclear proteins
revealed p130 to be modiﬁed by acetylation. NIH3T3
cells were synchronized in G0 by serum starvation for
72h. After stimulation through serum addition cells
were harvested at 2h intervals for a total of 24h.
Nuclear extracts were then prepared and analyzed by
immunoblotting with monclonal antibodies against
p130 (BD Transduction Laboratories, San Jose, CA,
USA) and acetylated lysine. Serum-starved cells in G0
showed substantial amounts of hypo-phosphorylated
p130 and low amounts of the slower migrating
hyperphosphorylated form of p130. During the time
course of the experiment the abundance of hypophos-
phorylated p130 continuously decreased, whereas the
amount of the hyperphosphorylated form increased
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stayed on a high level until G2-period (Figure 1a).
A corresponding cell cycle pattern of hypo- and hyper-
phosphorylated forms was also obtained when poly-
clonal p130 antibodies (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) were used for immunoblotting.
This pattern of hypo- and hyper-phosphorylated p130
has been previously reported for a time period of 12h
after serum addition in T98G cells by Hansen et al.
(2001). In G0 and G1 immunoblotting with anti-acetyl
lysine antibodies did not yield an immunosignal with
either hypo- or hyper-phosphorylated p130. However, in
early S-phase the hyperphosphorylated form of p130
shifted into the acetylated form as anti-acetyl lysine
antibodies yielded an immunosignal that co-migrated
with hyperphosphorylated p130; this band persisted
until late G2-period (Figure 1a). This result was
conﬁrmed with a speciﬁc antibody (a-K-1079ac) that
we raised against a C-terminal p130 peptide from amino
acids 1074–1085 containing K-1079 in the acetylated
state (SNSPSKacRLREIN; see results below). The cell
cycle distribution of cells was monitored by immuno-
detection of cyclin B1 (Figure 1a) and ﬂuorescence-
activated cell sorting analysis (not shown). These results
suggest that a signiﬁcant proportion of p130 in a
hyperphosphorylated state is acetylated in early S-phase
and is present in this state until late G2-period.
In order to further substantiate that hyperphosphory-
lated p130 is acetylated in S-phase, we performed small
interfering RNA knockdown of p130 and analyzed
S-phase nuclear extracts at 16h after serum addition by
immunoblotting using antibodies against p130, acety-
lated lysine residues and the speciﬁc antibody against
p130 acetylated at K-1079. The immunoblot with anti-
p130 antibodies clearly shows that the hypo- and hyper-
phosphorylated protein bands signiﬁcantly decreased in
si-p130 transfected cells; in line with this, the immuno-
blot with the antibody against the acetylated p130
peptide 1074–1085 (a-K-1079ac) showed a signiﬁcant
decrease of the slower migrating, hyperphosphorylated
p130 form (Figure 1b). A corresponding result was
obtained with anti-acetyl lysine antibodies; a glyceral-
dehyde 3-phosphate dehydrogenase knockdown control
corroborated the results (Figure 1b).
Figure 1 Cell cycle dependent abundance of p130 forms in NIH3T3 cells. (a) NIH3T3 cells were serum starved for 72h. After serum
addition cells were harvested at 2h intervals. Nuclei were isolated and nuclear extracts were prepared using NE-PER Nuclear and
Cytoplasmic Extraction Reagents (Pierce, Thermo Fisher Scientiﬁc, Rockford, IL, USA). Equal amounts of protein from each sample
were subjected to SDS–10% polyacrylamide gel electrophoresis (SDS–10% PAGE) with subsequent blotting to nitrocellulose. p130
was detected either with a monoclonal antibody (BD; BD Transduction Laboratories; No.610262) or with polyclonal antibodies (SC;
Santa Cruz, sc-317). Acetyl lysine was detected with a polyclonal antibody (Upstate, Millipore-Merck, Darmstadt, Germany; No.06-
933), acetylated p130 with a speciﬁc antibody that was raised in rabbits against a C-terminal p130 peptide (aa 1074-1085) where K-1079
is acetylated (a-K-1079ac), and cyclin B1 with a monoclonal antibody (Santa Cruz; sc-245). Arrows highlight the hyperphos-
phorylated, acetylated p130 forms. (b) Effect of si-p130 knockdown in synchronized S-phase cells at 16h after serum addition. Small
interfering RNA (siRNA) was purchased from Dharmacon (Lafayette, CA, USA; RBL2-p130-mouse siGENOME-ON-TARGET
plus set of four, glyceraldehyde 3-phosphate dehydrogenase (GAPDH)-mouse control) and resuspended in DEPC treated PBS. NIH-
3T3 cells were grown to 90% conﬂuency, and transfected with a mix of 4 RBL2/p130 siRNAs (100nm each) or GAPDH siRNA and
metafectene (ratio 1:4) according to the manufacturer’s instructions in serum free medium. Cells were serum starved for 72h, before
stimulation with 10% fetal calf serum to re-enter the cell cycle for 16h. Cells were then harvested, washed and nuclear extracts were prepared
using NE-PER. Proteins were separated by SDS–10% PAGE, blotted onto nitrocellulose and immunodetected using the indicated
antibodies. Bands were visualized using electrochemiluminescence.
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phorylated p130, we performed immunoprecipitation
using anti-p130 antibodies for precipitation of nuclear
extracts from NIH3T3 cells in G0 and S-phase. After
electrophoresis, immunoblotting was done with anti-
bodies against p130, acetyl lysine, and the acetylated
C-terminal p130 peptide (a-K-1079ac). Figure 2a shows
that anti-p130 antibodies precipitate p130 with the
hyperphosphorylated form being acetylated, as detected
by anti-acetyl lysine, as well as speciﬁc anti-p130-
K-1079ac antibodies. To get an idea of a possible
intracellular localization of acetylated p130, we analyzed
nuclear and cytoplasmic extracts from exponentially
growing NIH3T3 cells. Figure 2b shows that anti-acetyl
lysine antibodies detected acetylated p130 exclusively in
nuclear extracts, although the amount of hyperphos-
phorylated p130 is higher in the cytoplasmic extract. To
corroborate this result, we again used siRNA knock-
down of p130 in exponentially growing NIH3T3 cells
(Figure 2c). Immunoblotting of nuclear and cytoplasmic
extracts of si-p130 transfected cells revealed efﬁcient
downregulation of p130 in both forms (hypo- and
hyper-phosphorylated), whereas an small interfering-
glyceraldehyde 3-phosphate dehydrogenase control
yielded the localization pattern as seen in the untrans-
fected wild type (Figures 2b and c). As expected,
immunoblotting with the speciﬁc antibody against
acetylated p130 (a-K-1079ac) showed the acetylated
and hyperphosphorylated p130 in nuclear extracts of the
small interfering-glyceraldehyde 3-phosphate dehydro-
genase control, but neither in the cytoplasmic extract
of the small interfering-glyceraldehyde 3-phosphate
dehydrogenase control nor in the nuclear extracts of
si-p130 knockdown cells (Figure 2c). From these results,
we conclude that acetylated, hyperphosphorylated p130
is exclusively located in the nucleus, although the main
proportion of hyperphosphorylated p130 resides in the
cytoplasm (in a non-acetylated state).
As the total amount of p130 is very low in NIH3T3
cells, we expressed N-terminally FLAG-tagged p130
(Figure 3a) in insect cells and used the recombinant
protein for in vitro acetylation by the acetyltransferase
p300. Using radioactive acetyl-CoA as a co-substrate,
electrophoretic analysis and subsequent autoradiogra-
phy of the assay product revealed that p130 is acetylated
by p300 in vitro (Figure 3b; lane 4, autoradiography
panel). Corresponding assays were performed with
non-radioactive acetyl-CoA and acetylated p130,
as well as non-acetylated p130 were subsequently
analyzed by mass spectrometry. This revealed a
dominant acetylation site at K-1079 (Supplementary
Information; Figure 1) and minor acetylation at
K-1068 and K-1111 in the C-terminus and at K-128
and K-130 in the N-terminus. To substantiate these
ﬁndings, we expressed additional truncated p130
forms in insect cells (Figure 3a): FLAG-tagged versions
Figure 2 p130 from nuclear extracts exists in an acetylated form. (a) Nuclear extracts from synchronized NIH3T3 cells in G0-phase
(0h after serum addition) or S-phase (16h after serum addition) were immunoprecipitated with antibodies against p130
(BD Transduction Laboratories) coupled to Protein-G-Sepharose beads. After washing, beads (IP), supernatant (SN), as well as
nuclear extract (input, IN) were subjected to SDS–10% polyacrylamide gel electrophoresis (SDS–10% PAGE) with subsequent
immunoblotting using antibodies against p130 (BD), acetyl lysine or K-1079ac, respectively. As an immunoglobulinG control, nuclear
extract lanes were also incubated with secondary antibodies alone (c, control). Proteins were visualized with alkaline phosphatase
conjugated secondary antibodies. (b) Exponentially growing NIH3T3 cells were fractionated into nuclear and cytoplasmic extracts.
After SDS–10% PAGE and blotting onto nitrocellulose, p130 and acetylated p130 were detected by the corresponding antibodies.
(c) Exponentially growing NIH3T3 cells were transfected with si-p130 or small interfering-glyceraldehyde 3-phosphate dehydrogenase
(si-GAPDH) for 72h as described in the legend of Figure 1. After harvesting, cells were fractionated and samples were processed and
analysed as described above. Arrows highlight the position of acetylated p130.
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(115kDa), C-terminusþpocket domain (84kDa) and
C-terminus (14kDa). We used these proteins for radio-
active in vitro assays with p300 and subsequently
analyzed them by SDS–polyacrylamide gel electrophor-
esis and autoradiography. Figure 3b shows that the
ﬁve recombinant proteins were produced in sufﬁcient
quantity and quality (Coomassie panel) and approxi-
mately equal amounts were used for the p300-histone
acetyltransferase assay. As control we used chicken
erythrocyte histones. Autoradiography revealed that
full-length p130 and C-terminusþpocket domain con-
struct were labeled roughly equally, whereas the isolated
C-terminus exhibited particularly high acetylation by
p300 (Figure 3b, autoradiography panel). The truncated
p130 versions comprising the N-terminus and the
N-terminusþpocket were acetylated to a lesser extent.
As expected, autoacetylation of p300 and prominent
acetylation of core histones are visible. Note, that no
unspeciﬁc acetylation of contaminating minor proteins
Figure 3 Acetylation of p130 by p300 acetyltransferase in vitro takes place predominantly in the C-terminus and the major acetylation
site can be pinpointed to K-1079. (a) Schematic representation of N-terminally FLAG-tagged full-length p130, as well as truncated
versions expressed in Sf9 cells (baculovirus system). (b) Full-length and truncated versions of p130 were used for in vitro acetylation
assays. Proteins were incubated with p300 and 20mM
14C-acetylCoA for 30min at 371C, visualized by Coomassie blue stain (left panel)
and autoradiography (right panel) after SDS–10% polyacrylamide gel electrophoresis (SDS–10% PAGE). Histones and p300 were
used as controls. (c) Lysine residues found to be acetylated by MALDI-TOF/TOF mass spectrometry are shown in their respective
sequence environment. Ct, C-terminus; NLS, nuclear localization sequence; Nt, N-terminus.
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acetylation.
The fact that the C-terminus and the constructs that
contain the C-terminus are acetylated stronger than the
N-terminal constructs is in line with mass spectrometry
results that clearly identiﬁed a major acetylation site at
K-1079, whereas the other acetylated residues repre-
sented minor sites. Acetylated sites are depicted in
Figure 3c. The major acetylatable K-1079 is located
within one of two C-terminal nuclear localization
sequences, implying a possible effect on subcellular
localization of p130. Therefore, we performed transient
transfection experiments with C-terminal p130/GFP
constructs where K-1079 was mutated to arginine or
glutamine, but could not observe a signiﬁcant change of
nuclear localization of the reporter protein by micro-
scopy of transfected cells (results not shown), indicating
that a more subtle mechanism is modulating nuclear
localization of p130 rather than a simple K-1079
acetylation. This is in line with previous results
(Chestukhin et al., 2002), showing that functional
deletion of one of the two nuclear localization sequences
alone was not sufﬁcient to abolish nuclear localization
of p130, whereas only deletion of both resulted in
reduced nuclear localization (Chestukhin et al., 2002). In
this respect, it is interesting that all three acetylated
lysines in the C-terminus (K-1068, K-1079 and K-1111)
are in close neighborhood (3 or 4 amino acids) to
documented phosphorylation sites (S-1064, S-1076 and
S-1108; Hansen et al., 2001); in all three cases the
phosphorylated serine is followed by a proline. It is
tempting to speculate that the prolines might be
substrates of peptidyl-proline isomerases, which would
induce secondary structure changes. It has been shown
that a proline isomerase acts on prolines 30 and 38 of
histone H3, thereby modulating methylation of a
neighboring lysine (Nelson et al., 2006). An interrelation
between proline isomerization and p300 recruitment has
been demonstrated for p73 (Mantovani et al., 2004). The
fact of phosphorylation and acetylation sites together
with proline residues being clustered within few amino
acids, and all clusters being located within a region of
only 50 amino acids, suggests that the C-terminus of
p130 may be a region of particular regulatory potential
in the sense of a protein modiﬁcation code (Brosch et al.,
2008; Sims and Reinberg, 2008).
It has been shown that p130 is predominantly abundant
in G0-a n dG 1-phases (Claudio et al., 2002) and rapidly
decreases after S-phase (Classon and Dyson, 2001); in
NIH3T3 cells we did not observe such a rapid decrease of
p130. The modiﬁed forms of nuclear p130 rather persisted
through G2-period (Figure 1), a ﬁnding consistent with a
role for p130 in active G2-complexes (Popov et al.,2 0 0 5 )
and in cell cycle exit in G2 (Jackson et al.,2 0 0 5 ) .
To demonstrate a functional signiﬁcance of acetyla-
tion for the properties of p130, we analyzed p300-
mediated acetylation of p130 in the presence of the
human papilloma virus16 protein-E7 (HPV16-E7).
Pocket proteins have been shown to be targets of small
DNA virus oncoproteins, such as proteins from certain
types of papilloma-, polyoma- and adeno-viruses
(Felsani et al., 2006; White and Khalili, 2006). HPV16-
E7 binds to p130 and targets it for degradation;
moreover, histone deacetylases bind to p130 and the
E7 protein, thereby inhibiting histone deacetylase
binding to the E2F2 promoter and elevating the
acetylation of histones associated with E2F-responsive
promoters (Roman, 2006). We used full-length p130
protein, the C-terminusþpocket construct and the
N-terminus for radioactive in vitro acetylation by p300
in the presence or absence of HPV16-E7. Figure 4 shows
that E7 protein enhances p300 mediated acetylation of
full-length p130; this enhancement was even more
pronounced when the C-terminusþpocket was used as
a substrate, whereas no stimulating effect was detected
with the N-terminus. As control we used a polypeptide
of comparable molecular weight, Penicillium-antifungal
peptide, to rule out an unspeciﬁc protein effect.
Densitometric evaluation of autoradiograms of Figure 4
revealed that HPV16-E7 enhanced acetylation of
p130 full-length protein 1.28-fold, acetylation of p130-
C-terminusþpocket 1.65-fold, whereas acetylation of
p130-N-terminus was unaffected by HPV16-E7 (Supple-
mentary Table 1). Obviously, the E7 protein has a
substrate- and site-speciﬁc effect on p300 afﬁnity for
p130. The well-known binding of histone deacetylases to
p130 might not only be due to a targeting role of p130
for histone deacetylases to distinct promoters, but
may also reﬂect binding of the enzyme to exert its
catalytic activity on p130 for modulating its functional
properties. The functional changes of p130 induced
by de/acetylation most likely change its interaction
Figure 4 The human papillomavirus-16-E7 protein causes enhanced in vitro acetylation of p130 in the C-terminus (Ct). Full-length
p130 and truncated versions (C-terminusþpocket, N-terminus (Nt)) were incubated with
14C-acetylCoA and p300 in the presence or
absence of HPV16-E7 protein (2mg/100ml). As a control peptide the same amounts of Penicillium-antifungal peptide (PAF) were used.
Each reaction mix was subjected to SDS–10% polyacrylamide gel electrophoresis (SDS–10% PAGE; lower panel, Coomassie) with
subsequent autoradiography (upper panel).
Acetylation of p130
F Schwarze et al
5759
Oncogeneproperties with other proteins, as known from a number
of acetylatable non-histone proteins.
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